You are here

  • Home
  • Archive
  • Volume 79, Issue 11
  • Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need to use CRP?’ by Gonçalves et al

Article info

Article menu

Download PDFPDF

Correspondence response
Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need to use CRP?’ by Gonçalves et al
Free

Authors

  1. Correspondence to Dr Laura C Coates, University of Oxford, Oxford OX3 7LD, UK; laura.coates{at}ndorms.ox.ac.uk
View Full Text

Citation

van Mens LJJ, van de Sande MGH, van Kuijk AWR, et al
Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need to use CRP?’ by Gonçalves et al
Annals of the Rheumatic Diseases 2020;79:e143.

Publication history

  • Received July 11, 2019
  • Accepted July 12, 2019
  • First published July 22, 2019.
Online issue publication 
October 12, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.